Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (684)	1/26/2005 12:58:59 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

assume the news may leak, in which case I would expect TA to give some leading indication of the forthcoming good news. Hi,Peter I know you are a non-believer in TA.<g> Re: REGN, from a TA standpoint, it is on a down-trend on its monthly, weekly and daily charts.<g> On its daily chart, the downtrend that started on Jan.4 from the $3.07level is intact and the stock at present needs to close above $2.87 in order to break the downtrend. bigcharts.marketwatch.com On its weekly chart, the downtrend started on Sep.19 2003 at the $8.29 level and the stock needs to close above $3.50 bigcharts.marketwatch.com On the monthly chart, the downtrend coming from its March 2000 H at $18 was broken at $4.25 on March 28,2002 and the stock rallied to $8.47 on Sep.30 2003 when the downtrend started again.(It needs to close above $4.80 to break it.<g>) bigcharts.marketwatch.com As you said, there doesn't seem to be much expectation that the results of their secretin, or RG1068, in schizophrenic patients will show good results. I think they also have a trial going on evaluating Uridine for neurological disorders, and CTLA4-Ig their a monoclonal antibody,for R.A. and other autoimmune diseases. Their patent on CTLA4-IG which they licensed from the Univ. of Michigan. You, as a lawyer, know a lot more about the rightful claim of ownership of the patent in question. I thought that BMY claims that Dr.Craig Thompson from the U.M., collaborated with BMY scientists and that he is a rightful inventor on patents that were issued to BMY. I also thought that the Distric Court in Sep.2003 found that RGEN and the Univ. of Michigan were not sole or joint owners of the patent in question and that RGEN had appealed to the U.S. Court of the Federal Circuit with the final decision still pending. At any rate, if RGEN's volume starts picking up to the upside or it gets off its present downtrend, I will try to let you know.<g> RAGL Bernard

To: Biomaven who wrote (684)	1/26/2005 11:39:10 AM
From: Galirayo	Respond to of 3722

[RGEN] Hi Peter. I hear you. I don't believe in TA either. :D So I drew up a Chart for you. But after I did this I think I've changed my mind. So I'm going to Update and post another one later. I think it's more of a Channel. Which is still bullish as long as Trendline Support holds. ttrader.com In either case I see it's holding Support well today. Stay Tuned! Ray

To: Biomaven who wrote (684)	1/26/2005 1:27:38 PM
From: Galirayo	Respond to of 3722

[RGEN] Peter .. I think this is a more accurate Look at RGEN. The Trend Line I showed in the other chart needs to be observed closely as well ... But to me it looks like it has good support today. ttrader.com Cheers! Ray

To: Biomaven who wrote (684)	1/26/2005 5:41:07 PM
From: Galirayo	Respond to of 3722

Peter, Sergio said Hey ... and he saw things I did not. Message 20988135 Ray

To: Biomaven who wrote (684)	2/3/2005 12:32:12 PM
From: Galirayo	Respond to of 3722

[RGEN] A white candle tomorrow would confirm this. Message 21013150 Ray

To: Biomaven who wrote (684)	3/10/2005 10:12:36 PM
From: Galirayo	Read Replies (1) \| Respond to of 3722

Peter .. Bernard reminded me to remind you. Message 21123824 I noticed RGEN today. You may have as well. It's ready for a move up. IMHO stockcharts.com[w,a]dacayiay[dd][pb50!h.02,.20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G Ray

To: Biomaven who wrote (684)	5/18/2005 1:07:44 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Re: RGEN The stock has been performing better for the last week, but no news about any patents or results of their PII of RG1068, in schizophrenic patients. They reported an "Agreement" with ChiRhoClin,under which they will receive a payment of $750,000 and will be entitled to continue to market SecreFlo™ for the next several years under a royalty structure more favorable to RGEN than under the present Licensing Agreemen.RGEN is also not required to pay approximately $1.2M of disputed royalties and will record this amount as other income in the Q endeding on June 30. The stock started on a near term uptrend on May 10, but it still needs to close above its Apr.11 H of 2.04 The Relative Strenght Index has increased from 20 to 80 in the last week. The PSML & PS on RGEN at present: 1.87 1.82 1.78 1.81 & 1.70 (The L is still above the S & the M averages, but there seems to be good support at the 1.70 level.<g>) bigcharts.marketwatch.com bigcharts.marketwatch.com Bernard

To: Biomaven who wrote (684)	7/27/2005 12:07:16 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

RGEN Opened with an upgap and traded as high as 3.45 at 10.45 this morning as it reported 1stQ earnings of $0.07/shr vs. a loss of $0.02/shr in 2004. Revenues were up to $4.2M from $2.8M, but no news about the the patent litigation.<g> The stock still is up more than 30% for the day and hasn't closed its inital upgap. bigcharts.marketwatch.com Bernard

To: Biomaven who wrote (684)	1/30/2006 12:59:04 PM
From: Jibacoa	Respond to of 3722

P.S. I'd appreciate a heads-up if anyone notices anything of interest one way or the other. It seems to be acting well and could be getting ready to make a 52 wks. H Message 22113705 Bernard

To: Biomaven who wrote (684)	1/30/2006 1:04:25 PM
From: Galirayo	Read Replies (1) \| Respond to of 3722

[RGEN] Peter .. We've been discussing RGEN. Message 22113705

To: Biomaven who wrote (684)	2/27/2006 1:21:20 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

In its recent letter to the shareholders, RGEN's CEO Walter Herlihy makes reference to the patent concerning CTLA4-Ig for RA, which is the one that Peter mentioned on his note of Jan.25 last year. According to W.H., the FDA approved BMY's application for Orencia for RA treatment in December and in January RGEN & Michigan Univ. filed a complaint for infringement of US Patent No.6,685,941 which covers methods for using CTLA4-Ig for treating RA. He said that RGEN is seeking a royalty licensing agreement with BMY either by "litigation or negotiation".<g> They also have a claim pending against IMCL since Damon Biotech, a predecessor of RGEN had developed a cell line that contained their patented technology for the NCI to produce the monoclonal antibody wich IMCL now produces as Erbitux for treatment of colorectal Ca. Oral arguments for summary judgement on that claim were already held in February. RGEN Needs to close above 4.20 before it can test the resistance aove 4.45 and then the Feb.6 H at 5.08 <g> bigcharts.marketwatch.com RGEN had $23.076M in cash as of Dec.31 and expects to close the fiscal year ending next month about "breakeven" (with gross profits around $9M after total revenues of $12.5M ) It seems that RGEN has a good chance of reaching the $8 level in the next year and the R/R looks favorable, so I think that I will increase my position a little.<g> bigcharts.marketwatch.com Bernard

To: Biomaven who wrote (684)	7/31/2006 1:04:31 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

As previously mentioned on my post to Peter in February, RGEN's CEO Walter Herlihy made reference to the patent claims pending against BMY & IMCL in his letter to the shareholders. The patent claim against BMY is the one that Peter had mentioned, but the one that made today's spike on RGEN is the one against IMCL. RGEN's claim pattern against BMY is concerning methods for using CTLA4-Ig for treating RA based on US Patent No.6,685,941 which it owns together with Michigan Univ. & has to do with BMY's application for Orencia. On Friday the USA District Court in Massachusetts issued a Summary Judgment ruling in favor of RGEN & MIT in the patent lawsuit over the production of Erbitux. Patent 4,663,281 covers genetic elements that increase protein production in a mammalian cell, & IMCL reported that it had produced approximately $1B worth of Erbitux & BMY paid IMCL $900M as well as a 39% royalty on the net sales of Erbitux in the US. ( So it is possible that this was the patent that Peter was interested concerning BMY. <g>) At any rate, RGEN traded as high as $3.40 at 11.50AM & still is up 25% for the day on volume of 590,190 bigcharts.marketwatch.com Bernard